

Product Data Sheet

Product Name: Gemfibrozil-d6

Cat. No.: GC47397

Chemical Properties

Cas. No. 1184986-45-5

SMILES OC(C(C([2H])([2H])[2H])(C([2H])([2H])[2H])CCOC1=C(C=CC(C)=C1)C)=O


Formula C₁₅H₁₆D₆O₃ M.Wt 256.4

Solubility DMSO: soluble, Methanol: soluble Storage Store at -20°C

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution: ship with blue ice. All other available size: ship with RT, or blue ice upon request.

Structure



Background

Gemfibrozil-d₆ is intended for use as an internal standard for the quantification of gemfibrozil by GC- or LC-MS. Gemfibrozil is a peroxisome proliferator-activated receptor α (PPAR α) and PPAR γ agonist (EC₅₀s = 193.3 and 147.8 μ M, respectively, in transactivation assays).¹ *In vivo*, gemfibrozil (50 mg/kg, p.o.) reduces serum total cholesterol, triglyceride, and LDL levels in a rat model of high-cholesterol diet-induced hyperlipidemia.² Gemfibrozil (100 mg/kg per day) reduces atherosclerotic plaque area, superoxide production, and expression of the genes encoding the NF- κ B subunit p65 and chemokine (C-C) motif ligand 2 (CCL2) in *ApoE*^{-/-} mice.³ Formulations containing gemfibrozil have been used in the treatment of high cholesterol.

1. Kim, N.J., Lee, K.O., Koo, B.W., et al. Design, synthesis, and structure-activity relationship of carbamate-tethered aryl propanoic acids as novel PPAR α/γ dual agonists. *Bioorg. Med. Chem. Lett.* 17(13)3595-3598(2007) 2. Solanki, Y.B., and Jain, S.M. Antihyperlipidemic activity of Clitoria

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

ternatea and Vigna mungo in rats Pharm. Biol. 48(8)915-923(2010) 3. Calkin, A.C., Cooper, M.E., Jandeleit-Dahm, K.A., et al. Gemfibrozil decreases atherosclerosis in experimental diabetes in association with a reduction in oxidative stress and inflammation Diabetologia 49(4)766-774(2006)

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA